The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Abstract
Despite extensive investigation over the past three decades, cancer immunotherapy has produced limited success, with few agents achieving approval by the Food and Drug Administration and even the most effective helping only a minority of patients, primarily with melanoma or renal cancer. In recent years, immune checkpoints that maintain physiologic self-tolerance have been implicated in the down-regulation of anti-tumor immunity. Efforts to restore latent anti-tumor immunity have focused on antibody-based interventions targeting CTL antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells. Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment. Although ipilimumab can produce durable long-term responses in patients with advanced melanoma, it is associated with significant immune-related toxicities. By contrast, antibodies targeting either PD-1 or PD-L1 have produced significant anti-tumor activity with considerably less toxicity. Activity was seen in patients with melanoma and renal cancer, as well as those with non-small-cell lung, bladder and head and neck cancers, tumors not previously felt to be sensitive to immunotherapy. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation. Current efforts focus on registration trials of single agents and combinations in various diseases and disease settings and identifying predictive biomarkers of response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citationTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y.-B., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440
PD‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 414
Self-citationThompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386
Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994) · Genomics · doi:10.1006/geno.1994.1562 · Cited by 253
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & Weber, J. S. (2007) · International Immunology · doi:10.1093/intimm/dxm091 · Cited by 231
Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J.-C., Hamid, O., Powderly, J. D., Burris, H. A., Mokatrin, A., Kowanetz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3000 · Cited by 190
Sznol, M., Kluger, H. M., Callahan, M. K., Postow, M. A., Gordon, R. A., Segal, N. H., Rizvi, N. A., Lesokhin, A. M., Atkins, M. B., Kirkwood, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba9003 · Cited by 151
Self-citationPhase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hammers, H. J., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Razak, A. R. A., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4504 · Cited by 141
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Chen, A. C., Ready, N., & Rizvi, N. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8023 · Cited by 125
A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.
Lutzky, J., Antonia, S. J., Blake-Haskins, A., Li, X., Robbins, P. B., Shalabi, A. M., Vasselli, J., Ibrahim, R. A., Khleif, S. N., & Segal, N. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3001 · Cited by 105
Gettinger, S. N., Shepherd, F. A., Antonia, S. J., Brahmer, J. R., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Alaparthy, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8024 · Cited by 104
Cho, D. C., Sosman, J. A., Sznol, M., Gordon, M. S., Hollebecque, A., Hamid, O., McDermott, D. F., Delord, J., Rhee, I. P., Mokatrin, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4505 · Cited by 97
Powles, T. B., Vogelzang, N. J., Fine, G. D., Eder, J. P., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Teng, S.-L. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5011 · Cited by 96
Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.
Patnaik, A., Kang, S. P., Tolcher, A. W., Rasco, D. W., Papadopoulos, K. P., Beeram, M., Drengler, R. L., Chen, C., Smith, L. S., Perez, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2512 · Cited by 82
Antonia, S. J., Brahmer, J. R., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Shepherd, F. A., Laurie, S. A., Gerber, D. E., Goldman, J. W., Shen, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8113 · Cited by 79
Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
Brahmer, J. R., Rizvi, N. A., Lutzky, J., Khleif, S. N., Blake-Haskins, A., Li, X., Robbins, P. B., Vasselli, J., Ibrahim, R. A., & Antonia, S. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8021 · Cited by 78
Selby, M., Engelhardt, J., Lü, L., Quigley, M. M., Wang, C., Chen, B., & Korman, A. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3061 · Cited by 75
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
Atkins, M. B., Kudchadkar, R. R., Sznol, M., McDermott, D. F., Lotem, M., Schachter, J., Wolchok, J. D., Urba, W. J., Kuzel, T. M., Schuchter, L. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9001 · Cited by 65
Self-citation
Cited by
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Metadata
- Authors
- Philips, G. K., & Atkins, M.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-16
- Volume
- 27
- Issue
- 1
- Pages
- 39-46
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2118396147
- Cited by
- 335
- References
- 40
- FWCI
- 16.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.